PATENT CLAIM ANALYSIS

Application Number: 16033446
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "387000"]

Abstract:
The invention relates to 1,3-diaza-spiro-[3.4]-octane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.

Claim (Index 54):
The compound according to  claim 1 ,\n wherein R 1  means \u2014H or \u2014CH 3 ; R 2  means \u2014C 1 -C 6 -alkyl, linear or branched, saturated, unsubstituted; -cyclopropyl; or -cyclopropylmethylene; or R 1  and R 2  together with the nitrogen atom to which they are attached form a ring and mean -azetidine or -pyrrolidine; R 3  means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014CN, \u2014C 1 -C 4 -alkyl, \u2014CH 3 , \u2014CH 2 CH 3 , \u2014CH 2 F, \u2014CHF 2 , \u2014CF 3 , \u2014OCF 3 , \u2014OH, \u2014O\u2014C 1 -C 4 -alkyl, \u2014OCH 3 , \u2014C(\u2550O)NH 2 , C(\u2550O)NHCH 3 , \u2014C(\u2550O)N(CH 3 ) 2 , \u2014NH 2 , \u2014NHCH 3 , \u2014N(CH 3 ) 2 , \u2014NHC(\u2550O)CH 3 , \u2014CH 2 OH, SOCH 3  and SO 2 CH 3 ; or R 4  means\n \u2014H; \n \u2014C 1 -C 6 -alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014OH, \u2550O, \u2014S(\u2550O) 2 \u2014C 1 -C 4 -alkyl and \u2014O\u2014C 1 -C 4 -alkyl; \n 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014OH, and \u2014O\u2014C 1 -C 4 -alkyl, wherein said 3-6-membered cycloalkyl is connected through \u2014C 1 -C 6 -alkylene; \n 3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014OH, and \u2014O\u2014C 1 -C 4 -alkyl; wherein said 3-12-membered heterocycloalkyl is optionally connected through \u2014C 1 -C 6 -alkylene-, unsubstituted or substituted with \u2550O; \n 6-14-membered aryl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2014OH, and \u2014O\u2014C 1 -C 4 -alkyl; wherein said 6-14-membered aryl is optionally connected through \u2014C 1 -C 6 -alkylene- or \u2014S(\u2550O) 2 \u2014; \n R 5  means\n \u2014H; \n \u2014C 1 -C 6 -alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2550O, \u2014OH, \u2014O\u2014C 1 -C 4 -alkyl, \u2014O\u2014(CH 2 CH 2 \u2014O) 1-30 \u2014H, \u2014O\u2014(CH 2 CH 2 \u2014O) 1-30 \u2014CH 3 , \u2014C(\u2550O)OH, \u2014C(\u2550O)C 1 -C 4 -alkyl, \u2014C(\u2550O)OC 1 -C 4 -alkyl, \u2014C(\u2550O)NH 2 , \u2014C(\u2550O)NHC 1 -C 4 -alkyl, \u2014C(\u2550O)N(C 1 -C 4 -alkyl) 2 , \u2014(C\u2550O)-heterocycloalkyl, \u2014S(\u2550O)C 1 -C 4 -alkyl, \u2014S(\u2550O) 2 C 1 -C 4 -alkyl, \u2014NH 2 , \u2014NH\u2014C 1 -C 4 -alkyl, \u2014N(C 1 -C 4 -alkyl) 2 , \u2014NHC(\u2550O)\u2014C 1 -C 4 -alkyl, \u2014NH\u2014S(\u2550O) 2 C 1 -C 4 -alkyl; \n 3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CN, \u2550O, \u2014OH, \u2014C 1 -C 4 -alkyl, \u2014NH 2 , \u2014NH\u2014C I \u2014C 4 -alkyl, \u2014N(C 1 -C 4 -alkyl) 2 , \u2014NHC(\u2550O)\u2014C 1 -C 4 -alkyl, \u2014NHS(\u2550O) 2 \u2014C 1 -C 4 -alkyl, \u2014O\u2014C 1 -C 4 -alkyl, \u2014O\u2014(CH 2 CH 2 \u2014O) 1-30 \u2014H, \u2014O\u2014(CH 2 CH 2 \u2014O) 1-30 \u2014CH 3 , \u2014C(\u2550O)OH, \u2014C(\u2550O)OC 1 -C 4 -alkyl, \u2014C(\u2550O)C 1 -C 4 -alkyl, \u2014C(\u2550O)NH 2 , \u2014C(\u2550O)NHC 1 -C 4 -alkyl, \u2014C(\u2550O)N(C 1 -C 4 -alkyl) 2 , \u2014S(\u2550O)C 1 -C 4 -alkyl, \u2014S(\u2550O) 2 C 1 -C 4 -alkyl, -phenyl, \u2014C(\u2550O)-phenyl, \u2014C(\u2550O)-pyridyl, -pyridyl,-pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through \u2014C 1 -C 6 -alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through \u2014C\u2550O\u2014 or \u2014CH 2 \u2014C\u2550O\u2014; \n -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, \n imidazolyl, \n benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, \n benzoxazolyl, -pyrazolyl, \n quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, \n benzo[c][1,2,5]oxadiazolyl, \n imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl, in each case unsubstituted, mono- or polysubstituted; \n and R 6 , R 7 , R 8 , R 9 , R 10 , and R 11  mean \u2014H; or R 6  and R 7  together mean \u2550O and R 8 , R 9 , R 10 , and R 11  mean \u2014H.

Metadata:
- Claim Count in Document: 57.0
- Percentile: 95.0
- Lexical Diversity: 1.34375
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15417953', '15969907', '15403741', '13483170', '12281317']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7578703662503699
- 35 USC 102 Novelty (BERT): 0.5341556288142837
- Combined Prediction Score: 0.7354988925067613
- Mean Citation Score: 333.198664
- Max Citation Score: 350.52203
- Similarity Product: 270.7945360989177

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test